Relmada Therapeutics (NASDAQ: RLMD) director gets 164,000 stock appreciation rights

Rhea-AI Filing Summary

Relmada Therapeutics director Fabiana Fedeli reported receiving a grant of 164,000 stock appreciation rights on December 12, 2025. These derivative securities relate to Relmada Therapeutics common stock and carry an exercise price of $4.06 per right. The award was reported as an acquisition transaction and is held with direct ownership.

The stock appreciation rights are scheduled to vest in 16 equal quarterly installments, commencing on March 12, 2026, providing a staged vesting profile over time. The instruments become exercisable starting March 12, 2026 and have an expiration date of December 12, 2035, giving a long-dated window in which they may be exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fedeli Fabiana

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$4.06	12/12/2025		A		164,000		03/12/2026(1)	12/12/2035	Common Stock	164,000	$0	164,000	D

Explanation of Responses:

1. The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

	/s/ Fabiana Fedeli	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Relmada Therapeutics (RLMD) disclose in this filing?

Relmada Therapeutics reported that director Fabiana Fedeli received a grant of 164,000 stock appreciation rights on December 12, 2025, tied to the company’s common stock at an exercise price of $4.06 per right.

Who is the reporting person in the Relmada Therapeutics (RLMD) Form 4 and what is their role?

The reporting person is Fabiana Fedeli, who is identified in the filing as a director of Relmada Therapeutics, Inc. The form indicates that it is filed by one reporting person.

How many shares underlie the stock appreciation rights granted at Relmada Therapeutics (RLMD)?

The stock appreciation rights cover 164,000 derivative securities, with the underlying security listed as Relmada Therapeutics common stock in an amount or number of shares of 164,000.

What are the key terms of the stock appreciation rights granted by Relmada Therapeutics (RLMD)?

The filing states that the stock appreciation rights have an exercise price of $4.06, become exercisable starting on March 12, 2026, and have an expiration date of December 12, 2035.

What is the vesting schedule for the Relmada Therapeutics (RLMD) stock appreciation rights?

According to the explanation of responses, the stock appreciation rights vest in 16 equal quarterly installments, with vesting commencing on March 12, 2026.

Is the Relmada Therapeutics (RLMD) stock appreciation rights award held directly or indirectly?

The Form 4 indicates that after the reported transaction, the 164,000 derivative securities are held with direct (D) ownership, with no indirect beneficial ownership listed.